Source of Single-Tablet Abiraterone Data
The efficacy and safety data for the single-tablet 1000 mg abiraterone acetate formulation came from three pivotal randomized, placebo-controlled, international phase III clinical trials: COU-AA-301 (post-docetaxel setting), COU-AA-302 (pre-docetaxel setting), and a phase II therapeutic equivalence study for the fine-particle formulation. 1
Original 1000 mg Formulation Clinical Trials
The FDA approval of the standard 1000 mg abiraterone acetate tablet was based on two landmark studies:
COU-AA-301 (Post-Docetaxel Setting)
- Study design: 1,195 patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel were randomized 2:1 to receive abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg twice daily (n=797) versus placebo plus prednisone (n=398) 1
- Primary outcome: Overall survival improved from 10.9 months (placebo) to 14.8 months (abiraterone) at interim analysis (HR 0.65, P<0.001), and from 11.2 to 15.8 months at final analysis (HR 0.74, P<0.0001) 2, 1
- Secondary outcomes: Significant improvements in radiographic progression-free survival, PSA decline, and pain palliation 3
COU-AA-302 (Pre-Docetaxel Setting)
- Study design: Randomized phase III trial in asymptomatic or minimally symptomatic mCRPC patients without prior chemotherapy 2
- Primary outcome: Radiographic PFS improved from 8.3 to 16.5 months (HR 0.53, P<0.001) 2
- Overall survival: At final analysis with 49.2 months median follow-up, OS improved from 30.3 to 34.7 months (HR 0.81, P=0.003) 2
Fine-Particle 500 mg Formulation
In May 2018, the FDA approved a novel fine-particle formulation of abiraterone at 500 mg daily (half the dose of the original formulation) based on bioequivalence studies. 2
Phase II Therapeutic Equivalence Study
- Study design: 53 patients with mCRPC randomized to 500 mg daily fine-particle formulation plus 4 mg methylprednisolone twice daily versus 1000 mg originator formulation plus 5 mg prednisone twice daily 4, 2
- Bioequivalence confirmation: Based on serum testosterone levels, PSA response, and abiraterone pharmacokinetics 4, 2
- Safety profile: Similar rates of total and grade 3/4 adverse events between arms, with musculoskeletal disorders occurring more frequently in the originator-treated patients (37.9% vs 12.5%) 2
Castration-Sensitive Prostate Cancer Expansion
The February 2018 FDA approval for metastatic castration-sensitive prostate cancer (mCSPC) was based on two additional trials:
LATITUDE Trial
- Study design: 1,199 patients with high-risk mCSPC randomized to abiraterone plus prednisone 5 mg once daily versus placebo 2, 4
- Primary outcome: OS improved with HR 0.62 (P<0.0001); 3-year OS rates improved from 49% to 66% 2
- Final analysis: Median OS 53.3 vs 36.5 months (HR 0.66, P<0.0001) after 51.8 months follow-up 4
STAMPEDE Trial
- Study design: 1,917 patients with heterogeneous castration-sensitive disease (M1, N1, or high-risk M0) 4, 2
- Primary outcome: OS improved in overall population (HR 0.63, P<0.0001) and across all subgroups 4, 2
- Key finding: Survival benefit larger in patients <70 years (HR 0.51) versus ≥70 years (HR 0.94), with increased toxicity in older patients 2, 4
Important Clinical Context
All pivotal trials excluded patients with prior ketoconazole treatment for prostate cancer and those with adrenal gland or pituitary disorders. Concurrent spironolactone use was not permitted during study periods. 1 The standard 1000 mg dose must be taken on an empty stomach (fasting), while the fine-particle formulation can be taken with food, representing a significant practical advantage. 4, 2